1. Scrip

Quick Listen: Scrip's Five Must-Know Things

 
• By Ian Haydock

In this week's episode: what Trump might mean for pharma; Novo’s semaglutide hits mark in NASH; AstraZeneca leads the way in clinical trials; Viking’s weight loss data excite; and how to speed up MLR reviews.

Scrip Five Must Know Things
weekly audio roundup of selected content from Scrip's global team

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip‘s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 8 November 2024, including: what Trump might mean for pharma; Novo’s semaglutide hits mark in NASH; AstraZeneca leads the way in clinical trials; Viking’s weight loss data excite; and how to speed up MLR reviews.

This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

With Trump’s Return, Pharma Trades Disagreeable Knowns For Uncertainty

Novo Nordisk’s Semaglutide Hits Phase III Marks In NASH

AstraZeneca Leads The Way In Clinical Trials

Viking Excites With Latest Oral VK2735 Weight Loss Data

How To Speed Up MLR Reviews: A Master Class By J&J, UCB, ex-Takeda Heads

More from Scrip

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By Kevin Grogan

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Hengrui Renews Global Phase III Push As China Players Plan Pivotal Multinational Trials

 
• By Dexter Jie Yan

After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By Ian Haydock

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

More from Scrip's Five Must-Know Things

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: which big companies face the least LOE hit?; IPOs rise in 2024; Pfizer cuts last AAV gene therapy program; balance and focus suggested for globalizing Chinese firms; and Scrip Asks on therapeutic area advances.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: 2025’S biggest launches; 2024 deal metrics declined; GSK’s meningococcal vaccine; Arcus’s kidney cancer results; and Novartis on its India hub.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: delayed take-off for M&A?; Bain to acquire Mitsubishi Tanabe; clinical trials to look out for; how to work with Trump; and mid-cap biopharma winners and losers.